Last edition
News about Ingredients
Seasonal Flu Vaccines to Target Three Strains in 2026-27: EMA Guidance
The European Medicines Agency (EMA) has issued its recommendations for the influenza virus strains to be included in vaccines for the 2026–2027 seasonal flu campaign.
Ingredients | 02/04/2026 | By Darshana | 461
Mankind Pharma Acquires Rivotril Brand for India, Reinforcing Focus on Chronic CNS Therapies
Mankind Pharma Limited today announced that it has acquired the brand Rivotril from Roche for the Indian market, with exclusive rights to manufacture, market and distribute the product across the country. Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions.
Ingredients | 19/03/2026 | By Darshana | 142
Andera Partners Targets EUR 10 Billion AUM as It Accelerates Innovation and European Expansion
Andera Partners is reinforcing its long-term growth strategy by combining sustained investment activity, active portfolio management and strong fundraising momentum, despite a challenging economic environment marked in 2025 by a global slowdown and a more than 20 percent decline in private equity investments in France.
<br />
Ingredients | 23/02/2026 | By Darshana | 341
US Food and Drug Administration to Drop Two-Study Requirement for New Drug Approvals
The US Food and Drug Administration has announced plans to eliminate its long-standing expectation that new medicines be supported by at least two pivotal clinical trials, signaling a significant shift in regulatory policy aimed at accelerating patient access to innovative therapies.
Ingredients | 19/02/2026 | By Darshana | 165
Janux Therapeutics has entered into a global collaboration and exclusive licensing agreement with Bristol Myers Squibb to develop a novel cancer therapy for solid tumours. The partnership is valued at up to USD eight hundred fifty million, including upfront payments and development, regulatory, and commercial milestones.
Ingredients | 23/01/2026 | By Darshana | 183
Organon to Market Bempedoic Acid Therapy Nilemdo in Key European Markets
Organon, a global healthcare company focused on delivering impactful medicines and solutions for everyday health, has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo (bempedoic acid) across France, Denmark, Iceland, Sweden, Finland, and Norway.
Ingredients | 11/01/2026 | By Darshana | 396
Co-Diagnostics Inc, a molecular diagnostics company with a patented platform for developing molecular diagnostic tests, has received an Australian patent grant for its next-generation polymerase chain reaction (PCR) platform, reinforcing its intellectual property base supporting future manufacturing and commercialization.
Ingredients | 31/12/2025 | By Darshana | 162
Boehringer Advances First-in-Class Triple-Agonist Peptide for Obesity and CRM Disorders
Boehringer Ingelheim has announced the advancement of BI 3034701, a long-acting, potential first-in-class triple-agonist peptide being developed for the treatment of obesity. The progress marks a key milestone in the company’s strategy to tackle the global burden of obesity and its interlinked cardiovascular, renal, and metabolic (CRM) complications.
Ingredients | 09/12/2025 | By Darshana | 319
Citius Oncology Launches Lymphir, a Novel FDA-Approved Therapy for Relapsed or Refractory CTCL
According to Leonard Mazur, chairman and CEO of Citius Oncology and Citius Pharmaceuticals, the launch of Lymphir marks a major milestone for the company. He highlighted its median time to response of 1.4 months, noting that the therapy may provide rapid relief from the severe and debilitating itching associated with CTCL.
Ingredients | 04/12/2025 | By Darshana | 213
Zaynich milestone: First Indian-developed NCE accepted by US FDA
Wockhardt Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for its novel, first-in-class antibiotic Zaynich.
Ingredients | 02/12/2025 | By Darshana | 618
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy